Format

Send to

Choose Destination
See comment in PubMed Commons below
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):488-502. doi: 10.1016/j.ejpb.2013.08.011. Epub 2013 Aug 27.

Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration.

Author information

1
Laboratory of Pharmaceutical Technology/Centre of Research in Pharmaceutical Sciences (LTF/CICF), University of Porto, Porto, Portugal; Department of Physics and Chemistry, University of Southern Denmark, Odense M, Denmark. Electronic address: martins@sdu.dk.

Abstract

This study intended to investigate the ability of solid lipid nanoparticles (SLN) to deliver camptothecin into the brain parenchyma after crossing the blood-brain barrier. For that purpose, camptothecin-loaded SLN with mean size below 200 nm, low polydispersity index (<0.25), negative surface charge (-20 mV), and high camptothecin association efficiency (>94%) were produced. Synchrotron small and wide angle X-ray scattering (SAXS/WAXS) analysis indicates that SLN maintain their physical stability in contact with DMPC membrane, whereas SLN change the lamellar structure of DMPC into a cubic phase, which is associated with efficient release of the incorporated drugs. Cytotoxicity studies against glioma and macrophage human cell lines revealed that camptothecin-loaded SLN induced cell death with the lowest maximal inhibitory concentration (IC50) values, revealing higher antitumour activity of camptothecin-loaded SLN against gliomas. Furthermore, in vivo biodistribution studies of intravenous camptothecin-loaded SLN performed in rats proved the positive role of SLN on the brain targeting since significant higher brain accumulation of camptothecin was observed, compared to non-encapsulated drug. Pharmacokinetic studies further demonstrated lower deposition of camptothecin in peripheral organs, when encapsulated into SLN, with consequent decrease in potential side toxicological effects. These results confirmed the potential of camptothecin-loaded SLN for antitumour brain treatments.

KEYWORDS:

1,2-dimyristoyl-sn-glycero-3-phospho-choline; Apo E; Biodistribution; Brain targeting; CNS; Camptothecin; Cytotoxicity; DMEM; DMPC; DMPC membrane bilayer model; Dulbecco’s Modified Eagle’s Medium; FBS; Gliomas; HBSS; Hanks’ Balanced Salt solution; LDL; PBCA; Polysorbates; SAXS/WAXS; SEM; SLN; Solid lipid nanoparticles (SLN); apolipoprotein E; central nervous system; fetal bovine serum; low-density lipoprotein; polybutylcyanoacrylate; scanning electron microscopy; solid lipid nanoparticles; synchrotron small and wide angle X-ray scattering

PMID:
23994244
DOI:
10.1016/j.ejpb.2013.08.011
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center